Fig. 3

a Typical value and 95%CI of placebo group in clinical trials of ALS (OS and ALSFRS-R); b The typical OS under different baseline levels. Note: a The typical median OS (that is, the median duration of the patients was 17.8 months, and 90% of patients received Riluzole treatment) of placebo group was 29.0 (95% CI 24.5–34.5) months; and after treatment for 1, 2, and 4 years, the typical change from baseline ALSFRS-R scores in the placebo group were − 10.17 (95% CI − 11.92, − 8.55), − 15.52 (95% CI − 17.86, − 13.21), and − 20.23 (95% CI − 23.15, − 17.31), respectively. b the proportion of patients using Riluzole was fixed at 90%, when the disease duration was 9, 18 and 36 months, the median OS was 20.0, 29.0 and 35.5 months, respectively; the disease duration was fixed at 17.8 months, when the proportion of patients using Riluzole was 0%, 50% and 100%, the median OS was 25.5, 27.5 and 29.5 months, respectively